![The protease inhibitor atazanavir blocks hERG K+ channels expressed in HEK293 cells and obstructs hERG protein transport to cell membrane | Acta Pharmacologica Sinica The protease inhibitor atazanavir blocks hERG K+ channels expressed in HEK293 cells and obstructs hERG protein transport to cell membrane | Acta Pharmacologica Sinica](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Faps.2014.165/MediaObjects/41401_2015_Article_BFaps2014165_Fig1_HTML.jpg)
The protease inhibitor atazanavir blocks hERG K+ channels expressed in HEK293 cells and obstructs hERG protein transport to cell membrane | Acta Pharmacologica Sinica
![IJMS | Free Full-Text | HIV-Tat Exacerbates the Actions of Atazanavir, Efavirenz, and Ritonavir on Cardiac Ryanodine Receptor (RyR2) IJMS | Free Full-Text | HIV-Tat Exacerbates the Actions of Atazanavir, Efavirenz, and Ritonavir on Cardiac Ryanodine Receptor (RyR2)](https://www.mdpi.com/ijms/ijms-24-00274/article_deploy/html/images/ijms-24-00274-g003.png)
IJMS | Free Full-Text | HIV-Tat Exacerbates the Actions of Atazanavir, Efavirenz, and Ritonavir on Cardiac Ryanodine Receptor (RyR2)
![Atazanavir/ritonavir: a valuable once-daily HIV protease inhibitor with little impact on lipid profile | Future Virology Atazanavir/ritonavir: a valuable once-daily HIV protease inhibitor with little impact on lipid profile | Future Virology](https://www.futuremedicine.com/cms/10.2217/17460794.2.2.131/asset/images/medium/graphic2.gif)
Atazanavir/ritonavir: a valuable once-daily HIV protease inhibitor with little impact on lipid profile | Future Virology
![PDF) Model-Based Approach for Optimization of Atazanavir Dose Recommendations for HIV-Infected Pediatric Patients | Marc Pfister and M. Horga - Academia.edu PDF) Model-Based Approach for Optimization of Atazanavir Dose Recommendations for HIV-Infected Pediatric Patients | Marc Pfister and M. Horga - Academia.edu](https://0.academia-photos.com/attachment_thumbnails/41833377/mini_magick20190218-13622-aq286e.png?1550526736)
PDF) Model-Based Approach for Optimization of Atazanavir Dose Recommendations for HIV-Infected Pediatric Patients | Marc Pfister and M. Horga - Academia.edu
![Dolutegravir 50 mg thrice weekly plus atazanavir 400 mg daily in a long-term virologically suppressed HIV-infected patient - Massimiliano Lanzafame, Emanuela Lattuada, Stefano Nicolè, Fabio Rigo, Giulia Cucchetto, Ercole Concia, Sandro Vento, Dolutegravir 50 mg thrice weekly plus atazanavir 400 mg daily in a long-term virologically suppressed HIV-infected patient - Massimiliano Lanzafame, Emanuela Lattuada, Stefano Nicolè, Fabio Rigo, Giulia Cucchetto, Ercole Concia, Sandro Vento,](https://journals.sagepub.com/cms/10.1177/0956462416678164/asset/images/large/10.1177_0956462416678164-fig1.jpeg)
Dolutegravir 50 mg thrice weekly plus atazanavir 400 mg daily in a long-term virologically suppressed HIV-infected patient - Massimiliano Lanzafame, Emanuela Lattuada, Stefano Nicolè, Fabio Rigo, Giulia Cucchetto, Ercole Concia, Sandro Vento,
![ATV/r, ritonavir-boosted atazanavir; DRV/r, ritonavir-boosted darunavir. | Download Scientific Diagram ATV/r, ritonavir-boosted atazanavir; DRV/r, ritonavir-boosted darunavir. | Download Scientific Diagram](https://www.researchgate.net/publication/257840151/figure/fig2/AS:202919434559490@1425391171653/ATV-r-ritonavir-boosted-atazanavir-DRV-r-ritonavir-boosted-darunavir.png)
ATV/r, ritonavir-boosted atazanavir; DRV/r, ritonavir-boosted darunavir. | Download Scientific Diagram
![Individual atazanavir (ATV) area under the concentration time curve... | Download Scientific Diagram Individual atazanavir (ATV) area under the concentration time curve... | Download Scientific Diagram](https://www.researchgate.net/publication/311964438/figure/fig6/AS:962138424225813@1606403084642/Individual-atazanavir-ATV-area-under-the-concentration-time-curve-AUC-and-maximum.gif)
Individual atazanavir (ATV) area under the concentration time curve... | Download Scientific Diagram
![Distribution of atazanavir (ATV) C trough in human immunodeficiency... | Download Scientific Diagram Distribution of atazanavir (ATV) C trough in human immunodeficiency... | Download Scientific Diagram](https://www.researchgate.net/profile/Antonio-Di-Biagio-2/publication/221709143/figure/fig1/AS:601793222410260@1520490093586/Distribution-of-atazanavir-ATV-C-trough-in-human-immunodeficiency-virus-HIV-infected_Q320.jpg)
Distribution of atazanavir (ATV) C trough in human immunodeficiency... | Download Scientific Diagram
![ART, antiretroviral therapy; ATV, atazanavir; DRV/r, ritonavir-boosted... | Download Scientific Diagram ART, antiretroviral therapy; ATV, atazanavir; DRV/r, ritonavir-boosted... | Download Scientific Diagram](https://www.researchgate.net/profile/Takeshi-Nishijima-3/publication/257840151/figure/fig3/AS:669695996878865@1536679376606/Flow-diagram-of-patient-selection-ART-antiretroviral-therapy-ATV-atazanavir-DRV-r_Q320.jpg)
ART, antiretroviral therapy; ATV, atazanavir; DRV/r, ritonavir-boosted... | Download Scientific Diagram
![Effect of Adherence as Measured by MEMS, Ritonavir Boosting, and CYP3A5 Genotype on Atazanavir Pharmacokinetics in Treatment‐Naive HIV‐Infected Patients - Savic - 2012 - Clinical Pharmacology & Therapeutics - Wiley Online Library Effect of Adherence as Measured by MEMS, Ritonavir Boosting, and CYP3A5 Genotype on Atazanavir Pharmacokinetics in Treatment‐Naive HIV‐Infected Patients - Savic - 2012 - Clinical Pharmacology & Therapeutics - Wiley Online Library](https://ascpt.onlinelibrary.wiley.com/cms/asset/8e59251d-5983-45fa-8ae7-0eea364ee0d9/cptclpt2012137-fig-0005-m.jpg)
Effect of Adherence as Measured by MEMS, Ritonavir Boosting, and CYP3A5 Genotype on Atazanavir Pharmacokinetics in Treatment‐Naive HIV‐Infected Patients - Savic - 2012 - Clinical Pharmacology & Therapeutics - Wiley Online Library
![RCSB PDB - 3EL9: Crystal structure of atazanavir (ATV) in complex with a multidrug HIV-1 protease (V82T/I84V) RCSB PDB - 3EL9: Crystal structure of atazanavir (ATV) in complex with a multidrug HIV-1 protease (V82T/I84V)](https://files.rcsb.org/pub/pdb/validation_reports/el/3el9/3el9_multipercentile_validation.png)
RCSB PDB - 3EL9: Crystal structure of atazanavir (ATV) in complex with a multidrug HIV-1 protease (V82T/I84V)
![Structure of the budget impact model. Abbreviations: ATV, atazanavir;... | Download Scientific Diagram Structure of the budget impact model. Abbreviations: ATV, atazanavir;... | Download Scientific Diagram](https://www.researchgate.net/publication/314158597/figure/fig1/AS:467557657387008@1488485840394/Structure-of-the-budget-impact-model-Abbreviations-ATV-atazanavir-NRTI-nucleoside.png)
Structure of the budget impact model. Abbreviations: ATV, atazanavir;... | Download Scientific Diagram
![RCSB PDB - 3EL9: Crystal structure of atazanavir (ATV) in complex with a multidrug HIV-1 protease (V82T/I84V) RCSB PDB - 3EL9: Crystal structure of atazanavir (ATV) in complex with a multidrug HIV-1 protease (V82T/I84V)](https://cdn.rcsb.org/images/structures/3el9_assembly-1.jpeg)
RCSB PDB - 3EL9: Crystal structure of atazanavir (ATV) in complex with a multidrug HIV-1 protease (V82T/I84V)
![1 Atazanavir (ATV) With Ritonavir (RTV) or Saquinavir (SQV) vs Lopinavir/Ritonavir (LPV/RTV) in Patients With Multiple Virologic Failures 24-Week Results. - ppt download 1 Atazanavir (ATV) With Ritonavir (RTV) or Saquinavir (SQV) vs Lopinavir/Ritonavir (LPV/RTV) in Patients With Multiple Virologic Failures 24-Week Results. - ppt download](https://slideplayer.com/8206585/33/images/slide_1.jpg)
1 Atazanavir (ATV) With Ritonavir (RTV) or Saquinavir (SQV) vs Lopinavir/Ritonavir (LPV/RTV) in Patients With Multiple Virologic Failures 24-Week Results. - ppt download
![Flow diagram of patient selection. ART, antiretroviral treatment; ATV,... | Download Scientific Diagram Flow diagram of patient selection. ART, antiretroviral treatment; ATV,... | Download Scientific Diagram](https://www.researchgate.net/publication/250926447/figure/fig2/AS:341287736758283@1458380745307/Flow-diagram-of-patient-selection-ART-antiretroviral-treatment-ATV-atazanavir-PIs.png)